GlassScriptPhysician profile
Sergio Garcia
NPI 1548462740
$977.65
in general payments reported to CMS, 2019-2025
13 companies · $61.32 in 2025
The $61.32 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $392 · 2020: $238 · 2022: $286 · 2025: $61.32.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $61.32.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $61.32 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $158.65 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $123.51 | 2020 | |
| Metuchen Pharmaceuticals | $118.72 | 2019 | |
| Eisai INC. | $114.54 | 2020 | |
| Jazz Pharmaceuticals INC. | $109.02 | 2019 | |
| Insmed, INC. | $99.99 | 2019 | |
| Novastep INC. | $89.83 | 2022 | |
| Becton, Dickinson and Company | $46.17 | 2025 | Hemosphere |
| Medtronic Vascular, INC. | $41.76 | 2019 | |
| Abbvie INC. | $37.63 | 2022 | |
| Pfizer INC. | $22.68 | 2019 | |
| Gilead Sciences, INC. | $15.15 | 2025 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sergio Garcia listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.